109 related articles for article (PubMed ID: 3022909)
1. CA-125. Use as a tumor marker with mixed mesodermal tumors of the female genital tract.
Peters WA; Bagley CM; Smith MR
Cancer; 1986 Dec; 58(12):2625-7. PubMed ID: 3022909
[TBL] [Abstract][Full Text] [Related]
2. Serum CA 125 in ovarian pathology and its variation in ovarian carcinoma after integrated therapy.
Pansini F; Bellinazzi A; Rainaldi V; Santoiemma M; Lenzi B; Jacobs M; Mollica G; Bagni B
Gynecol Obstet Invest; 1986; 21(1):47-51. PubMed ID: 3005141
[TBL] [Abstract][Full Text] [Related]
3. The value of cancer antigen-125 as a tumor marker in malignant germ cell tumors of the ovary.
Altaras MM; Goldberg GL; Levin W; Darge L; Bloch B; Smith JA
Gynecol Oncol; 1986 Oct; 25(2):150-9. PubMed ID: 2428701
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin combination chemotherapy in mixed mesodermal sarcoma of the female genital tract.
Jansen RL; van der Burg ME; Verweij J; Stoter G
Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1131-3. PubMed ID: 3115787
[TBL] [Abstract][Full Text] [Related]
5. Malignant mixed mesodermal tumors of the uterus and ovary treated with cisplatin-based combination chemotherapy.
Grosh WW; Jones HW; Burnett LS; Greco FA
Gynecol Oncol; 1986 Nov; 25(3):334-9. PubMed ID: 3023205
[TBL] [Abstract][Full Text] [Related]
6. Prospective trial of cisplatin, adriamycin, and dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary.
Baker TR; Piver MS; Caglar H; Piedmonte M
Am J Clin Oncol; 1991 Jun; 14(3):246-50. PubMed ID: 2031513
[TBL] [Abstract][Full Text] [Related]
7. Serial CA 125 levels during chemotherapy for metastatic or recurrent endometrial cancer.
Fanning J; Piver MS
Obstet Gynecol; 1991 Feb; 77(2):278-80. PubMed ID: 1988893
[TBL] [Abstract][Full Text] [Related]
8. Pathologic complete response of advanced ovarian mixed mesodermal tumor to cisplatin, adriamycin and dacarbazine: a case report.
Fanning J; Zylstra S; Tsukada Y; Piver MS
Eur J Gynaecol Oncol; 1989; 10(6):365-7. PubMed ID: 2560718
[TBL] [Abstract][Full Text] [Related]
9. Tissue CA 125 and CA 19-9 in malignant, mixed mesodermal tumors of the uterus.
Podczaski E; Kaminski P; Hackett TE; Olt GJ; Zaino R
Gynecol Oncol; 1993 Apr; 49(1):56-60. PubMed ID: 8387061
[TBL] [Abstract][Full Text] [Related]
10. [Platinum-based combination chemotherapy for malignant mixed mesodermal tumor of the ovary: a case report].
Hamaguchi K; Okura N; Nagasue N; Nishimura H; Yakushiji M; Harataka J
Nihon Gan Chiryo Gakkai Shi; 1990 Nov; 25(11):2717-23. PubMed ID: 2177492
[TBL] [Abstract][Full Text] [Related]
11. Initial assessment of tumor-associated antigen CA-125 in patients with ovarian, cervical, and testicular tumors.
Buamah PK; Cornell C; Skillen AW; Cantwell BM; Harris AL
Clin Chem; 1987 Jul; 33(7):1124-5. PubMed ID: 3036401
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma.
Kivinen S; Kuoppala T; Leppilampi M; Vuori J; Kauppila A
Obstet Gynecol; 1986 Apr; 67(4):468-72. PubMed ID: 3008051
[TBL] [Abstract][Full Text] [Related]
13. Use of serum CA-125 in monitoring patients with uterine sarcoma. A preliminary report.
Patsner B; Mann WJ
Cancer; 1988 Oct; 62(7):1355-8. PubMed ID: 3166396
[TBL] [Abstract][Full Text] [Related]
14. Monitoring the cytotoxic potential of a sequential polychemotherapy (adriamycin/cisplatin-vincristine/cyclophosphamide-high dose methotrexate) in patients with advanced ovarian cancer with the tumor marker CA-125.
Sevelda P; Dittrich C; Salzer H; Pateisky N; Spona J
Cancer Detect Prev; 1986; 9(5-6):521-8. PubMed ID: 3465442
[TBL] [Abstract][Full Text] [Related]
15. CA 125 in gynecologic practice.
Malkasian GD; Podratz KC; Stanhope CR; Ritts RE; Zurawski VR
Am J Obstet Gynecol; 1986 Sep; 155(3):515-8. PubMed ID: 2428248
[TBL] [Abstract][Full Text] [Related]
16. [A case of recurrent endometrial cancer (clear cell adenocarcinoma) remarkably responsive to combination chemotherapy containing cisplatin].
Kitayama S; Iwahashi M; Iwahashi M; Yamoto M; Nakano R
Gan To Kagaku Ryoho; 1989 May; 16(5):2099-101. PubMed ID: 2730095
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of advanced ovarian mixed mesodermal tumors and treatment with doxorubicin- and cis-platinum-based chemotherapy.
Plaxe SC; Dottino PR; Goodman HM; Deligdisch L; Idelson M; Cohen CJ
Gynecol Oncol; 1990 May; 37(2):244-9. PubMed ID: 2160905
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of CA 19-9 as a tumor marker for gynecologic malignancies].
Inoue M; Saitoh J; Abe Y; Inoue Y; Ueda G; Tanizawa O; Gamoh Y; Dan A; Satoh T
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Nov; 37(11):2411-4. PubMed ID: 3865972
[No Abstract] [Full Text] [Related]
19. Identification of an ectopic developmental antigen that appears in malignant ascitic fluid.
Nakai M; Ishikawa M; Kawauchi H
Eur J Obstet Gynecol Reprod Biol; 1991 Nov; 42(1):61-9. PubMed ID: 1663874
[TBL] [Abstract][Full Text] [Related]
20. Use of cisplatin, doxorubicin, and cyclophosphamide to treat advanced and recurrent adenocarcinoma of the endometrium.
Hancock KC; Freedman RS; Edwards CL; Rutledge FN
Cancer Treat Rep; 1986 Jun; 70(6):789-91. PubMed ID: 3731140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
